Clinical trial registry record

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 12, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05456828
Last registry update
June 12, 2026
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
Visara, Inc.
Enrollment
56
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
56
Population
ALL · 50 Years to 80 Years
Duration
2023-02-10 to 2025-11-03
Intervention
ASKG712
Comparator
Not reported
Outcomes measured
Incidence of ocular adverse events (AEs) of the study eyes — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks; Incidence of non-ocular adverse events (AEs) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks; Area under the concentration time curve (AUC) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks; Maximum plasma concentration (Cmax) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks; Anti-Drug Antibody — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks; Mean change from baseline in best corrected visual acuity (BCVA) as measured by Early Treatment of Diabetic Retinopathy…; Mean change from baseline in central subfield thickness (CST) of macula measured by optical coherence tomography (OCT)…; Mean change from baseline in choroidal neovascularization area measured by fundus angiography — Part 1: 6 weeks; Part 2…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON